Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse
Biomolecules · 29.08.2023 · 13 (9) · 1324
DOI: 10.3390/biom13091324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 29.08.2023. Verfasst von Jessica Dennison und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, State of Florida Department of Health Ed and Ethel Moore Alzheimer’s Disease Research Program, NIH National Institute of Aging.
Abstract (Originalsprache)
Epigenetic compounds have become attractive small molecules for targeting the multifaceted aspects of Alzheimer’s disease (AD). Although AD disproportionately affects women, most of the current literature investigating epigenetic compounds for the treatment of AD do not report sex-specific results. This is remarkable because there is rising evidence that epigenetic compounds intrinsically affect males and females differently. This manuscript explores the sexual dimorphism observed after chronic, low-dose administration of a clinically relevant histone deacetylase inhibitor, chidamide (Tucidinostat), in the 3xTg-AD mouse model. We found that chidamide treatment significantly improves glucose tolerance and increases expression of glucose transporters in the brain of males. We also report a decrease in total tau in chidamide-treated mice. Differentially expressed genes in chidamide-treated mice were much greater in males than females. Genes involved in the neuroinflammatory pathway and amyloid processing pathway were mostly upregulated in chidamide-treated males while downregulated in chidamide-treated females. This work highlights the need for drug discovery projects to consider sex as a biological variable to facilitate translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Diabetes Research Institute, Division of Endocrinology, Diabetes, and Metabolism, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
ORCID-Profile: Claes Wahlestedt, Claude-Henry Volmar
Förderung
- NIA NIH HHS
- State of Florida Department of Health Ed and Ethel Moore Alzheimer’s Disease Research Program
- NIH National Institute of Aging
Zitieren
APA
Dennison, J., Mendez, A., Szeto, A., Lohse, I., Wahlestedt, C., & Volmar, C. H. (2023). Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse. Biomolecules, 13(9), 1324. https://doi.org/10.3390/biom13091324
Vancouver
Dennison J, Mendez A, Szeto A, Lohse I, Wahlestedt C, Volmar CH. Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse. Biomolecules. 2023;13(9):1324. doi:10.3390/biom13091324
BibTeX
@article{Dennison2023,
author = {Dennison, Jessica and Mendez, Armando and Szeto, Angela and Lohse, Ines and Wahlestedt, Claes and Volmar, Claude-Henry},
title = {Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {9},
pages = {1324},
doi = {10.3390/biom13091324}
}
EUVIMED